Algorithme Pharma
Algorithme Pharma, doing business as Altasciences, is a mid-size early-phase contract research organization providing preclinical safety testing, Phase I-II clinical pharmacology, bioanalysis, and manufacturing services to biopharmaceutical companies of all sizes across North America.
- Company typePrivate
- Founded1992
- HeadquartersLaval, Canada
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Algorithme Pharma does
Algorithme Pharma, doing business as Altasciences, is a mid-size early-phase contract research organization headquartered in Laval, Canada, with clinical operations now spanning Canada and the United States (including a Los Angeles Phase I-II clinic). Founded in 1992, the company employs 501-1,000 staff and positions itself as a single-vendor partner for biopharmaceutical sponsors of all sizes, covering preclinical safety testing (GLP and non-GLP), clinical pharmacology from first-in-human through end of Phase II, bioanalytical services from preclinical through Phase IV, formulation development, Phase I-through-commercial manufacturing, and ICH stability testing.
The core technology offering is the proprietary "Acceleration Platform," an integrated preclinical-to-proof-of-concept workflow complemented by a "Tell Us Once" sponsor data management program and a "Proactive Drug Development" methodology. The platform's marketed claim is a reduction in program duration of up to 40 percent, anchored in part on a published case study advancing an incretin-based therapy from safety assessment to proof-of-concept in approximately 22 months. Operations are supported by GLP-compliant facilities and ICH stability testing capabilities, enabling submission-ready documentation.
The business model is fee-for-service professional services revenue, with study or program pricing negotiated on a project-by-project basis (no public pricing). Go-to-market is enterprise sales-led, with dedicated business development and account management teams engaging biopharma decision-makers directly across North America. Marketing is content-driven and built around the "Altascientist" scientific journal (now distributed as an audiobook), webinars, video, industry events, and a 30,000+ VIP subscriber base. Customers span enterprise pharmaceutical companies (Idenix, a wholly-owned Merck subsidiary; Ionis Pharmaceuticals), mid-market biotechs (NeuroTrauma Sciences, Locemia Solutions), and emerging sponsors (gIcare Pharma), with therapeutic scope spanning standard small-molecule and biologic studies, biosimilars, and specialized assessments such as human abuse potential, QT, and renal/hepatic impairment.
Algorithme Pharma firmographics
Firmographics- Name
- Algorithme Pharma
- Legal name
- Altasciences
- Website
- https://algopharm.com
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Algorithme Pharma, doing business as Altasciences, is a mid-size early-phase contract research organization providing preclinical safety testing, Phase I-II clinical pharmacology, bioanalysis, and manufacturing services to biopharmaceutical companies of all sizes across North America.
- Ownership category
- akta.pro rank
Algorithme Pharma industry classification
Industry- Product category
- Contract Research Organization (CRO) / Early Phase Drug Development Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where Algorithme Pharma is headquartered
LocationHeadquarters
- HQ city
- Laval
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
Algorithme Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Preclinical Services: Fee-for-service preclinical safety assessments for small and large molecules including GLP toxicology, safety pharmacology, pharmacokinetics, and immunotoxicology studies. Revenue is project-based with studies scoped individually for each sponsor.
- Clinical Services: Clinical pharmacology trials from first-in-human through end of Phase II, including proof-of-concept studies, bioavailability/bioequivalence, and specialized populations. Revenue generated through per-study contracts with pharmaceutical and biotech sponsors.
- Manufacturing and Analytical Services: Formulation development, Phase I through commercial manufacturing, and ICH stability testing. Revenue from contract manufacturing and analytical testing services.
- Bioanalysis Services: Bioanalytical laboratory services supporting preclinical through Phase IV studies, available as standalone or integrated package. Revenue from analytical testing contracts.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels9 records
Algorithme Pharma product offering
Product offeringCore offering
Algorithme Pharma, operating as Altasciences, is a mid-size early phase contract research organization (CRO) offering biopharmaceutical companies preclinical safety testing, clinical pharmacology trials from first-in-human through end of Phase II, bioanalytical laboratory services, and manufacturing and analytical services. The company provides integrated drug development support from lead candidate selection to proof of concept, operating facilities in Canada and the United States.
Differentiator
Problem solved
Functional benefit
Brands
- The Altascientist: Scientific journal published by the company
Products and services
- Preclinical Services
Quantifiable outcome
- Reduce program durations by up to 40%
- +1 more outcomes
Companies that use Algorithme Pharma
Customer profileNamed customers6 records
Segments2 records
Ideal customer profiles2 records
Algorithme Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Algorithme Pharma partnerships and signals
Strategic signalScale indicators3 records
Recent moves4 records
Expansion highlights5 records
Algorithme Pharma competitors and assessment
Company assessmentDirect peers
- Celerion: Celerion is a closely comparable early-phase clinical pharmacology CRO offering first-in-human through Phase II services, bioanalysis, and specialized PK studies — directly overlapping Altasciences' core clinical pharmacology footprint.
- Worldwide Clinical Trials: Worldwide Clinical Trials focuses on early-stage clinical development and bioanalytical services for biopharma, positioning it as a direct peer in the Phase I–II clinical pharmacology and bioanalysis segments.
Broad incumbents
- Charles River Laboratories: Charles River is a global CRO/CDMO with a dominant preclinical and early-phase clinical presence, including safety assessment, bioanalysis, and Phase I capabilities that overlap Altasciences' preclinical services and bioanalysis offerings.
- Parexel International: Parexel is a Tier 1 global CRO offering early-phase clinical, bioanalysis, and regulatory services to biopharma, representing a broader incumbent alternative for sponsors evaluating Altasciences.
- IQVIA: IQVIA is the largest global CRO with Phase I clinical, bioanalytical, and R&D consulting capabilities across the entire development continuum, competing with Altasciences on enterprise biopharma RFPs.
- Labcorp Drug Development (Covance): Labcorp/Covance operates central laboratories, bioanalytical services, and early-phase clinical operations globally, overlapping with Altasciences on bioanalysis and early clinical trial testing.
- SGS Life Sciences (SGS Santé): SGS operates a global clinical and bioanalytical CRO business with early-phase and central laboratory services that compete for biopharma early-development outsourcing work.
- Eurofins Discovery / Bioanalytical Services: Eurofins' BioPharma Product Testing and discovery services include bioanalytical and preclinical capabilities that overlap with Altasciences' bioanalysis and research support offerings.
- Medpace: Medpace is a mid-to-large full-service CRO with growing early-phase and bioanalytical capabilities, representing a competitive alternative for biotech sponsors evaluating Altasciences for early development work.
Emerging players
- Frontage Laboratories: Frontage provides bioanalytical, CMC, and early clinical development services to biopharma — an adjacent specialty CRO whose bioanalysis work directly competes with Altasciences' Bioanalysis Services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Algorithme Pharma social profiles
Digital presenceAlgorithme Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Algorithme Pharma leadership team
Management profileNumber of profiles
Profiles1 record
Algorithme Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Algorithme Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Algorithme Pharma
What does Algorithme Pharma do?
Algorithme Pharma, operating as Altasciences, is a mid-size early phase contract research organization (CRO) offering biopharmaceutical companies preclinical safety testing, clinical pharmacology trials from first-in-human through end of Phase II, bioanalytical laboratory services, and manufacturing and analytical services. The company provides integrated drug development support from lead candidate selection to proof of concept, operating facilities in Canada and the United States.
Is Algorithme Pharma a public or private company?
Algorithme Pharma is a private company. It is classified as unknown and is currently operating.
When was Algorithme Pharma founded?
Algorithme Pharma was founded in 1992. It employs 501 to 1,000 people.
Where is Algorithme Pharma based?
Algorithme Pharma is headquartered in Laval, Canada, in the North America region.
How does Algorithme Pharma make money?
Four revenue lines are on record. Preclinical Services are the primary driver. The others are clinical Services, manufacturing and Analytical Services and bioanalysis Services.
Who are Algorithme Pharma's main competitors?
Direct peers on record are Celerion and Worldwide Clinical Trials. Broad incumbents are Charles River Laboratories, Parexel International, IQVIA, Labcorp Drug Development (Covance), SGS Life Sciences (SGS Santé), Eurofins Discovery / Bioanalytical Services and Medpace. Frontage Laboratories is listed as an emerging player.
Does Algorithme Pharma have an API?
No public API is recorded for Algorithme Pharma.
What industry is Algorithme Pharma in?
Algorithme Pharma's product category is Contract Research Organization (CRO) / Early Phase Drug Development Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 5417 and its SIC code is 8731.